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Abstract
Purpose Pregnancy characteristics have been associated
with breast cancer risk, but information is limited on their
relationship with breast density. Our objective was to
examine the relationship between first pregnancy charac-
teristics and later life breast density, and whether the
association is modified by genotype.
Methods The Marin Women’s Study was initiated to
examine breast cancer in a high-incidence mammography
population (Marin County, CA). Reproductive character-
istics and pregnancy information including pregnancy-
induced hypertension (PIH) were self-reported at the time
of mammography. Forty-seven candidate single nucleotide
polymorphisms were obtained from saliva samples; seven
were assessed in relation to PIH and percent fibroglandular
volume (%FGV). Breast density assessed as %FGV was
measured on full-field digital mammograms by the San
Francisco Mammography Registry.
Results A multivariable regression model including 2,440
parous women showed that PIH during first pregnancy was
associated with a statistically significant decrease in %FGV
(b = -0.31, 95 % CI -0.52, -0.11), while each month of
breast-feeding after first birth was associated with a sta-
tistically significant increase in %FGV (b = 0.01, 95 % CI
0.003, 0.02). PIH and breast-feeding associations with
%FGV were modified by age at first birth. In a subsample
of 1,240 women, there was evidence of modification in the
association between PIH and %FGV by specific vascular
endothelial growth factor (VEGF) (rs3025039) and insulin
growth factor receptor-1 (IGFR1) (rs2016347) gene
variants.
Conclusion These findings suggest that first pregnancy
characteristics may exert an influence on extent of breast
density later in life and that this influence may vary
depending on inherited IGFR1 and VEGF genotypes.
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Background
Parity and age at first birth consistently have been shown to
be associated with breast cancer risk in women worldwide
(e.g., [1]). The mechanisms underlying the protective effect
of pregnancy include a reduction in the number of mam-
mary stem cells, an alteration in the responsiveness of the
breast to estrogens, differentiation of mammary epithelial
cells, and a change in the levels of circulating hormones (as
reviewed in [2]). In addition to the difference in breast
cancer risk between nulliparous and parous women, there is
evidence that the characteristics of pregnancy, particularly
first birth, affect breast cancer risk. An increased risk of
breast cancer has been associated with having had a
pregnancy that resulted in a preterm birth [3], higher
birthweight (e.g., [4]), or multifetal gestation [3], and a
decreased risk has been found with having had a pregnancy
in which the woman developed hypertension or pre-
eclampsia [3, 5], had a smaller placental weight [6], or had
nausea or vomiting [7, 8]. Investigators have found that
pregnancy characteristics may be particularly important in
the first birth, and with a late age at first birth (e.g., [3]).
The relationship between pregnancy characteristics and
breast density has received little attention. Breast density
has an established, strong relationship to breast cancer.
Research has suggested that this relationship is causal
rather than correlational (e.g., [9]) thus providing a
potentially important surrogate target for prevention stud-
ies. While research has consistently shown a negative
association between increasing parity and breast density
(e.g., [10, 11]), findings have been less consistent for an
association between breast density and older age at first
birth (as reviewed in [12]). A few studies have demon-
strated that some of the same birth characteristics shown to
be associated with increased breast cancer risk were asso-
ciated with high breast density, specifically, preterm birth,
nulliparity/low parity, older age at first birth, and high birth
weight [10, 11, 13, 14]. Lope et al. [14] found that duration
of breastfeeding was positively associated with breast
density, while Butler et al. [10] found no significant asso-
ciation between breast-feeding and breast density.
A better understanding of the association between first
pregnancy and breast density could inform breast cancer
prevention efforts. If first birth characteristics are found to
be associated with breast density in the same direction as
their association with breast cancer, this would indicate
that these pregnancy events affect breast cancer through
their impact on breast density. This study therefore aimed
to examine the association between first pregnancy and
breast density (Study 1). We additionally endeavored to
further explore whether the association between first
pregnancy and breast density varied by candidate germline
gene variants, specifically single nucleotide polymor-
phisms (SNPs) known to be related to breast cancer, breast
density, or pregnancy characteristics (Study 2).
Materials and methods
Study participants
This study was conducted using data from women enrolled
in the Marin Women’s Study (MWS). The MWS is a cross-
sectional study conducted at mammography centers in
Marin County, California associated with Kaiser Perma-
nente, Sutter Health (Novato Community Hospital), and
Marin General Hospital. It is estimated that 80 % of
mammograms conducted in Marin residents are conducted
at centers affiliated with these health care facilities, rep-
resenting approximately 38,000 women annually. These
mammography sites are also included in the San Francisco
Mammography Registry (SFMR), one of seven registries
included in the National Cancer Institute Breast Cancer
Surveillance Consortium. Risk factors and saliva speci-
mens collected in the MWS are linked with breast density,
measured as percent fibroglandular volume (%FGV), and
breast cancer outcome.
At the time of analysis, there were 11,361 women
enrolled in the MWS; for purposes of this analysis (Study
1), women were excluded if they were missing data on age
(n = 80), if they reported ever having been diagnosed with
breast cancer (n = 751), if they reported taking antiestro-
gens (n = 107), if they had never had a live birth
(n = 2,814), if they did not have a measure of breast
density assessed as %FGV (n = 4,326), if they had missing
data on any of the model variables (n = 639), if they
reported having had a hysterectomy with ovarectomy
(n = 160), or if their first birth was not a singleton birth
(n = 44), leaving an analysis population of 2,440.
Exposure assessment
Primary data collection in the MWS includes self-report
information from a questionnaire. Women are asked to
report in-depth information on their reproductive history,
including information on life course socioeconomic status,
alcohol use, and use of exogenous hormones, and data on
other established breast cancer risk factors, including
family history. Reproductive history includes parity and
age at first birth, and for each pregnancy women are asked
to report multifetal gestation, duration of breast-feeding,
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low and high birth weight (\2,500 g, [4,000 g), preterm
birth, pregnancy weight gain (pounds), and high blood
pressure during pregnancy [or pregnancy-induced hyper-
tension (PIH)] (yes/no). Self-reported height and weight
are collected from the SFMR.
At the time of entry into the MWS, women are asked
whether they are willing to donate a saliva specimen.
Those who consent to donate a saliva sample (89 % of
population) are sent a kit in the mail and asked to return the
tube of donated saliva in a preaddressed and postage-paid
envelope to the Buck Institute for Research on Aging
where the saliva is logged, stored, and processed. The
specimens are processed by separation into supernatant
available for steroid hormone analysis, and a cellular
component from which DNA is isolated using Invitrogen’s
PureLink Genomic DNA kits. Samples are stored in the
MWS Biorepository housed at the Buck Institute in
Novato, California.
Selection of SNP candidates
For Study 2, participants were also selected from the MWS
population and were drawn from among 2,400 participants
for whom SNP data were available from donated saliva
samples.
Twenty-five preselected candidate SNPs were multiplexed
and analyzed in the MWS DNA samples by InterGenetics, Inc
(Oklahoma City, OK) in parallel with analysis of their panel of
22 OncoVue SNPs. All SNP assays were performed and
evaluated as previously described [15], and the CLIA-
approved 22 SNP OncoVue assay and algorithm were pre-
viously validated as a new individualized breast cancer risk
estimator using buccal DNA samples from an earlier
(1997–1999) Marin County case–control study cohort [16].
Selection of the novel 25 SNP candidates evaluated in the
present study followed a detailed literature search of SNPs
reported in GWAS studies to be significantly associated (in at
least one published report) to specific exposures, outcomes,
and hypothesized breast cancer associated pathways of rele-
vance to the current MWS. In cases where there were more
than one SNP from a given gene, weight of literature, linkage
characteristics, and potential functionality based on specific
location of the SNP within the gene were considered. Gene
frequency was also a major selection criterion to ensure
adequate power for analysis. For purposes of the analysis
examining interactions with PIH reported in this paper, we
evaluated SNPs in the following seven genes: eNOS (NOS3),
ESR2, VEGF, EDN1, IL-10, HCFXI (KLKB1), IGFR1.
Outcome assessment
Each participant in the study was required to have under-
gone a screening mammogram. One of the novel features
of this study is the measure of %FGV assessed by the
method single-energy X-ray absorptiometry (SXA) [17–20].
This method uses a calibration phantom of the same
thickness as the compressed breast, circumventing some of
the problems associated with other breast density measures
including their subjectivity and lack of absolute reference
standards [19]. The first generation calibration phantom
(Gamma) used for this method has provided preliminary
data on 8,600 women to show that %FGV is reproducible
to approximately 2 % between successive measures and
accurate to known standards of breast composition using
reference phantoms [17]. Investigators have demonstrated
that %FGV is inversely correlated with age, body mass
index (BMI), and menopausal status, as expected for a
measurement of breast density, and is positively associated
with breast cancer risk [20]. %FGV data are collected by
the SFMR at all sites in Marin County which employ
digital mammography and are obtained from the SFMR
through a cooperative agreement. Data used in this study
were obtained using version 6.5 of the SXA software.
The MWS was approved by the participating institu-
tions, and participants provided written informed consent
for participation in the study.
Statistical analysis
Multivariable linear regression analyses were conducted to
examine the associations between %FGV and reproductive
factors, controlling for relevant confounders. Robust regres-
sion techniques were used to minimize the effects of outliers
and influential observations (i.e., observations that have a
large impact on the regression analysis). All models con-
trolled for a base set of confounding variables, including
current age, BMI, race, education, smoking, family history of
breast cancer (whether a first degree relative has been diag-
nosed with breast cancer), hysterectomy status, menopausal
status, and exogenous hormone use at the time of the mam-
mogram. Prior to regression, %FGV was square root trans-
formed to normalize the distribution.
All genotyping data were checked for compliance of
single-gene allelic frequencies with Hardy–Weinberg fre-
quency expectations using v2 goodness-of-fit test. Bivariate
associations between the genotypes of the SNPs and
%FGV were examined. Multivariable linear regression
models were constructed adjusting for potential con-
founders including current BMI, age, race, and age of first
live birth, and interaction terms were generated for the
genotype of each SNP compared to a baseline genotype.
Statistical tests were conducted to examine the interaction
term for each level of the SNP compared to the baseline
level of the SNP, as well as for the joint interaction effect
of each SNP overall and PIH, and p values examined for
statistical significance.
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Results
The distribution of covariates and the mean %FGV for each
level of the covariate are presented in Table 1. The vast
majority of the women were White, had a college degree, and
were postmenopausal. The mean %FGV was 35.3. In these
unadjusted analyses, there were significant associations
between %FGV and age, menopausal status, BMI, race,
education, smoking status, hysterectomy status, and age at
menarche; all associations were in the expected directions.
The distribution of reproductive characteristics and the
mean %FGV for the different levels of the characteristics is
presented in Table 2. In this population, 47.9 % gave birth
for the first time at age 30 or older and 23 % had only one
birth. There were significant crude associations between
%FGV and months of breast-feeding, parity, age at first
birth, birthweight, and PIH.
Table 3 presents the results of multivariable models
examining the effect of first birth characteristics on breast
density overall and stratified by age at first birth. Because
the results are presented in units corresponding to the
square root transformation of %FGV, the point estimates
are not interpretable on a %FGV scale, but can be inter-
preted in terms of the magnitude of the effect.
Overall, having experienced high blood pressure during
the first pregnancy was associated with a significantly lower
%FGV (-0.31; 95 % CI -0.52, -0.11). In addition, each
month of breast-feeding was associated with a significantly
increased %FGV (0.01; 95 % CI 0.003, 0.02). Late menar-
che (age 15? vs. before age 10) was associated with a bor-
derline significant increase in %FGV (0.26; 95 % CI -0.04,
0.56). This model explained 49 % of the variance in %FGV.
Models were stratified by whether the first birth occur-
red before age 30 or at age 30 or later to examine whether
these associations varied by age at first birth (Table 3).
Among women with a first birth before age 30, each month
of breast-feeding was borderline significantly associated
with an increase in breast density (0.01; 95 % CI 0.0002,
0.03). In addition, having had a low birthweight infant was
associated with a borderline significantly decrease in
%FGV (-0.29; 95 % CI -0.57, 0.002), and having had a
late menarche was associated with a borderline significant
increase in %FGV (0.32; 95 % CI -0.05, 0.69). In women
whose first birth occurred at age 30 or later, the model
estimates were similar to those in the overall population.
Having experienced high blood pressure during the first
pregnancy was associated with a significant decrease in
%FGV (-0.42; 95 % CI -0.71, -0.13), and months of
breast-feeding were associated with a significant increase
in %FGV (0.01; 95 % CI 0.001, 0.02). While the model
explained 44 % of the variance in %FGV in women whose
first birth was age 30 or greater, it explained 38 % of the
variability in women whose first birth was age \30 years.
Table 1 Mean percent fibroglandular volume (%FGV) by study
population characteristics (Study 1)
Characteristic Parous women (n = 2,440)
n Mean %FGV
(SD)
All women 2,440 35.3 (21.0)
Age
B 45 481 49.4 (22.5)
46–55 756 39.1 (22.00)
56–65 680 28.4 (16.0)
[65 523 25.8 (14.2)
F statistic, p value 169.71, p \ 0.001
Menopausal status
Premenopausal 940 46.3 (22.7)
Postmenopausal 1,500 28.4 (16.4)
F statistic, p value 509.2, p \ 0.001
Current exogenous hormone use
No 2,042 35.4 (21.4)
Yes 398 34.9 (18.8)
F statistic, p value 0.18, p = 0.67
Body mass index (BMI)
Underweight (\18.5) 56 62.6 (25.9)
Normal weight (18.5–24.9) 1,525 42.3 (20.5)
Overweight (25–29.9) 578 23.2 (11.6)
Obese (30 ?) 260 16.4 (9.0)
F statistic, p value 305.45, p \ 0.001
Race
White 2,214 35.1 (21.00)
Black 9 32.3 (25.3)
Asian 96 40.4 (21.6)
Other 41 41.9 (23.2)
Hispanic 80 31.6 (16.5)
F statistic, p value 3.13, p = 0.01
Education
HS or less 109 28.1 (17.1)
Some college 614 29.7 (17.1)
College or post graduate 1,717 37.8 (21.9)
F statistic, p value 41.80, p \ 0.001
Smoking History
Never 1,383 37.7 (21.9)
Current 74 32.00 (18.1)
Former 983 32.1 (19.3)
F statistic, p value 21.81, p \ 0.001
Hysterectomy status
No 2,192 36.3 (21.2)
Yes 248 26.8 (17.1)
F statistic, p value 46.41, p \ 0.001
Menarche
10 or younger 93 29.8 (19.3)
11–14 2,089 34.7 (20.6)
15? 258 41.8 (22.8)
F statistic, p value 16.72, p \ 0.001
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Because of the significant protective associations between
PIH and %FGV, and the consistency of this finding with those
in the literature indicating a significantly protective effect of
PIH on breast cancer, we analyzed salivary DNA samples to
determine whether interactions existed for the associations
between PIH and %FGV based on seven SNPs previously
shown to be associated with PIH (Online Resource 1). For this
analysis, participants were excluded if they had a history of
breast cancer or use of antiestrogens, if they did not have a valid
%FGV measurement, or if they had never had a live birth,
leaving an analysis sample size of 1,240, which was further
reduced in multivariable models because of missing data on
one or more of the variables included in the model, including
SNP results when genotyping was not successful for that SNP.
In line with the Study 1 analysis that was limited to reproduc-
tive characteristics in the first pregnancy, our Study 2 definition
for the exposure was limited to the development of PIH in first
pregnancy. All of the seven SNPs were found to be in com-
pliance with Hardy–Weinberg frequency expectations. In this
Study 2 subset, %FGV was lower in women with a history of
PIH, although this finding did not reach statistical significance.
None of the bivariate associations between the genotypes of the
seven selected SNPs and %FGV were statistically significant.
Multivariable analyses indicated no significant interac-
tions between PIH and five of the seven SNPs tested
(Table 4); however, two of the seven SNPs were associated
with PIH. A borderline significant interaction was found
between the CT genotype of the VEGF SNP and PIH on
%FGV (p = 0.063) (compared to the CC genotype). The TT
genotype, which has the lowest frequency, did not occur in
any of the women with PIH in the first pregnancy and thus
does not appear in the results. Statistically significant inter-
actions were found between PIH and the GT genotype of the
IGFR1 SNP (p = 0.01) (compared to the GG genotype);
those with PIH and the GT genotype had significantly lower
%FGV than those with GG genotype of the IGFR1 SNP (joint
interaction term p value = 0.03). A borderline significant
interaction was found between the TT genotype of the IGFR1
SNP and %FGV (compared to the GG genotype) (p = 0.07).
This group was only half the size of the GT group, which may
explain why, despite the apparent larger effect seen in the
graphic, this did not reach statistical significance. The main
effects terms for the GT and TT genotypes of the IGFR1 SNP
were both 0.18 in this multivariable model that included the
interaction terms. Both of these sets of interactions are pre-
sented visually in Figs. 1 and 2, below.
In this case, it can be seen that having PIH and the CC
genotype resulted in no change in %FGV, while having
PIH with the CT genotype resulted in a decrease in %FGV.
Discussion
In this cross-sectional study, we found that PIH during first
pregnancy was associated with significantly reduced breast
density measured by %FGV in later life, the effect of
which was greatest in those women whose first birth
Table 2 Mean percent fibroglandular volume (%FGV) by first
pregnancy risk factors (Study 1)
Characteristic Parous women (n = 2,440)
n Mean %FGV (SD)
Months of breast-feeding
0 460 27.2 (15.4)
1–3 434 32.4 (18.7)
4–6 547 35.2 (20.9)
7–12 666 39.1 (21.9)
[12 333 42.9 (24.1)
F, p 37.72, p \ 0.001
Parity
1 563 36.8 (22.5)
2 1,219 36.1 (21.0)
3 482 34.0 (19.7)
4 142 29.0 (17.5)
5? 34 25.6 (16.5)
F, p 6.66, p \ 0.001
Age at first birth
\20 110 25.9 (17.0)
20–29 1,161 30.8 (18.1)
30–34 680 39.5 (21.7)
35? 489 42.2 (23.6)
F, p 55.37, p \ 0.001
Birthweight
Low 178 33.1 (20.2)
High 262 32.1 (19.5)
Normal 2,000 35.9 (21.2)
F, p 4.84, p = 0.01
Pregnancy high blood pressure
No 2,284 35.6 (21.0)
Yes 156 30.9 (19.8)
F, p 7.21, p = 0.01
Weeks gestation
38? 2,227 35.3 (21.1)
36–37 156 36.4 (20.7)
B35 57 32.00 (18.3)
F, p 0.92, p = 0.40
Pregnancy weight gain (lbs)
0 or weight loss 5 20.8 (13.9)
1–10 50 35.0 (21.3)
11–25 912 35.2 (21.1)
26–40 1,064 35.3 (20.7)
[40 409 35.8 (21.5)
F, p 0.65, p = 0.62
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occurred at age 30 or later, where preeclampsia and ges-
tational hypertension (or PIH) are more prevalent. To our
knowledge, this is the first study to identify an association
between experience of a pregnancy affected by PIH/ges-
tational hypertension and %FGV. PIH has been fairly
consistently associated with a reduction in breast cancer
risk (e.g., [5, 21]), though some studies have found no (e.g.,
[6, 22]) or even increased risk [23, 24]. PIH is a multi-
factorial disease with genetic and environmental factors
known to be involved in its etiology although full under-
standing of its pathogenesis remains elusive despite dec-
ades of research [25]. Likewise, the mechanism by which
PIH affects breast cancer risk is unknown although
potentially via the same etiologic basis as PIH, with the-
ories focusing on placental dysfunction and a subsequent
lowering of circulating estrogens [26], increase in serum
insulin-like growth factor [27], and/or angiogenic factors
[28]. In support of the theory of an altered hormonal milieu
are findings such as those of Cerhan et al. [29] who found
non-significantly reduced breast density in women born
from a pregnancy in which their mothers experienced
eclampsia/preeclampsia [29], and similar findings reported
in a systematic review by Xue and Michels [30] who found
significantly decreased risk of breast cancer if a woman’s
mother had experienced preeclampsia or eclampsia.
In this study, PIH was shown to significantly interact
with specific allelic variants of insulin growth factor
receptor-1 (IGFR1; rs2016347), and borderline signifi-
cantly with a specific allelic variant of vascular endothelial
growth factor-A (VEGF-A; rs3025039) genes, indicating
that the protective effects of first pregnancy PIH on later
life breast density and breast cancer risk may depend on
inherited functional variants in these two growth factor
receptor and angiogenic factor genes. Prior studies
involving these allelic variants support this conclusion,
since the VEGF-A SNP investigated (rs3025039) has been
repeatedly linked to decreased plasma levels of VEGF and
reduced breast cancer risk, [31–33] while the IGFR1 SNP
investigated (rs2016347) has not only been previously
associated with breast density but also found to be an
independent prognostic marker for breast cancer recurrence
[34, 35]). While these various sources of evidence make it
unlikely that these two SNPs found to modulate the sig-
nificant association between PIH and %FGV were simply
false positive discoveries, these novel observations require
additional validation in larger population-based studies
Table 3 Linear regression model: percent fibroglandular volume (%FGV) in parous MWS women with %FGV measurement and model
variables (Study 1)
Overall (n = 2,440) Age at first birth
\30 (n = 1,271) 30 ? (n = 1,169)
Parity (number: 1–5) 0.02 (-0.04, 0.08) 0.01 (-0.06, 0.08) -0.05 (-0.16, 0.07)
High blood pressure (vs. no) -0.31 (-0.52, -0.11)* -0.24 (-0.53, 0.06) -0.42 (-0.71, -0.13)*
Breast-feeding (months) 0.01 (0.003, 0.02)* 0.01 (0.0002, 0.03) 0.01 (0.001, 0.02)*
Gestational weight gain (lbs) -0.002 (-0.01, 0.002) -0.0001 (-0.01, 0.01) -0.002 (-0.01, 0.01)
Birthweight (vs. normal)
Low -0.04 (-0.26, 0.18) -0.29 (-0.57, 0.002) 0.05 (-0.31, 0.40)
High -0.04 (-0.21, 0.12) 0.01 (-0.21, 0.22) -0.02 (-0.28, 0.23)
Weeks gestation (versus 38 ? weeks)
36–37 weeks 0.08 (-0.14, 0.29) 0.24 (-0.05, 0.54) 0.03 (-0.28, 0.35)
\35 weeks -0.02 (-0.40, 0.35) 0.23 (-0.29, 0.76) -0.002 (-0.55, 0.54)
Menarche (vs. \10)
11–14 0.07 (-0.19, 0.33) 0.07 (-0.24, 0.39) -0.08 (-0.52, 0.37)
15? 0.26 (-0.04, 0.56) 0.32 (-0.05, 0.69) -0.04 (-0.54, 0.47)
Age at first birth (vs. \20)
20–29 -0.01 (-0.26, 0.24) NA NA
30–34 0.01 (-0.26, 0.28)
35? 0.13 (-0.15, 0.41)
R2 0.49 0.38 0.44
Controlled for current age, BMI, race, education, smoking, first degree relative with breast cancer, hysterectomy status, menopausal status
(except in models stratified by hysterectomy status), and hormone use at the time of the mammogram
* Differences significant at the p \ 0.05 level
 Differences significant at the p \ 0.10 level
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given the strong inheritance pattern underlying breast
density.
Duration of breast-feeding in first pregnancy was asso-
ciated with increased %FGV later in life in our overall
study population and in women regardless of age at first
birth (though these findings were of borderline signifi-
cance). Our finding of a positive association between
duration of breast-feeding and %FGV is in agreement with
that of Lope et al. [14], who found a positive association
between breast density (using the cumulus method) and
duration of lactation, but conflicts with those of others who
found no association (e.g., [10, 25]) or an inverse associ-
ation between breast-feeding and breast density (e.g., [36]).
Differences in the timing and measurement of breast
Table 4 Multivariate
associations between genotypes










EDN_GT9PIH -0.178 0.58 266
EDN_TT9PIH 0.300 0.70 0.77 38
HCFX CC 374
HCFX_CT9PIH -0.004 0.99 323
HCFZ_TT9PIH -0.263 0.57 0.84 75
NOS3 CC 124
NOS3_CT9PIH 0.075 0.85 342
NOS3_TT9PIH 0.176 0.68 0.91 305
IL10 CC 186
IL10_CT9PIH -0.020 0.95 365
IL10_TT9PIH -0.116 0.76 0.95 214
VEGF CC VEGF_CT9PIH -0.621 0.06 NA 557
200
IGFR1 GG 174
IGFR1_GT9PIH -0.906 0.01 389
IGFR1_TT9PIH -0.734 0.07 0.03 195
ESR2 CC 131
ESR2_CT9PIH 0.403 0.31 379
ESR2_TT9PIH -0.053 0.90 0.60 251
Fig. 1 Interaction of PIH and VEGF Fig. 2 Interaction of PIH and IGFR1
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density between these diverse studies are the most likely
explanation for their disparate associations, though this
could also be due to basic differences in the study popu-
lations. Although breast-feeding has been thought to pro-
duce an overall protective effect against breast cancer (e.g.,
[37]), many studies find no association (e.g., [22]) and
recent systematic reviews of the topic fail to support an
association (e.g., [38, 39]). More research is needed in the
area of breast-feeding and breast health to better elucidate
whether a protective effect exists, and if so, when and how
breast-feeding might affect breast density.
A number of other first pregnancy factors were less
consistently associated with %FGV, but were suggestive in
certain sub-analyses, including gestational weight gain,
infant birthweight, and preterm birth. Other authors have
found associations between breast density and birthweight
[11, 14] and preterm birth and breast density [11]. While
our data were suggestive of relationships between %FGV
and these birth characteristics, our findings were neither
consistent nor strong. The differences may be due to dif-
ferences in the breast density measure or characteristics of
the study populations, including differences in the age
structure (only 55 and younger in El-Bastawissi et al. [11]
and 45–68 in Lope et al. [14]).
This study has a number of important strengths, including a
large sample size, a contemporary sample, a novel measure of
breast density, and the availability of a wide variety of
reproductive characteristics for study. The primary limitation
in this study is the use of self-reported data for reproductive
history. Though it is possible that women may not accurately
recall information about their first pregnancy, particularly if it
occurred in the distant past, we would expect that they would
accurately recall the major events including their age, an
experience of PIH, and breast-feeding. To the extent that
recall bias is present, it would be nondifferential (i.e., not
associated with %FGV), and would thus bias the results
toward the null. Another limitation is that, despite the fact that
the overall sample size in this study was large, the sample size
was small for specific subgroup analyses. Studies with larger
populations may be better able to detect significant associa-
tions between birth characteristics and breast density where
they exist. Selection bias may be present in the sample of
patients providing saliva samples for the SNP analyses;
women who consented to donate saliva were significantly
more likely to be of White Non-Hispanic race and to be of
higher socioeconomic status based on education and income,
but were not significantly different in terms of family history
of breast cancer or current age. While this may limit the
generalizability of the findings indicating an interaction
between PIH and VEGF and IGFR1 on %FGV, any selection
bias present should not limit the validity of the findings.
Finally, this study was intentionally restricted to first births,
but it will be important to determine whether the findings for
first birth characteristics hold for all births or whether they are
unique to the first birth (e.g., whether total duration of breast-
feeding has the same association with breast density as
duration of breast-feeding after the first birth).
Conclusion
In summary, we found associations between first birth
characteristics and breast density measured as %FGV that
confirmed and extended the few published findings on birth
characteristics and breast density. PIH was associated with a
decrease in breast density and breast-feeding an increase in
breast density, which may help elucidate the pathway by
which they operate to affect breast cancer. Variation in the
association between PIH and %FGV by genotype of IGFR1
and VEGF suggest that the protective effect of PIH on breast
density may vary between women depending on genotype.
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